CORCEPT THERAPEUTICS INC Operating Lease Liability
CORCEPT THERAPEUTICS INC (CORT) had Operating Lease Liability of $9.42 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-07-29
- 2026-06-30: Operating Lease, Liability $9.42M.
- 2026-03-31: Operating Lease, Liability $9.64M.
- 2025-12-31: Operating Lease, Liability $6.11M.
- 2025-09-30: Operating Lease, Liability $6.36M.
| Period end | Operating Lease, Liability | Operating Lease, Liability as first filed |
|---|---|---|
| 2026-06-30 | $9.42M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $9.64M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $6.11M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $6.36M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $6.61M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $6.83M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $6.94M 10-K · filed 2025-02-26 | |
| 2024-09-30 | $6.79M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $5.67M 10-Q · filed 2024-07-29 | |
| 2024-03-31 | $76.00K 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $151.00K 10-K · filed 2024-02-15 | |
| 2023-09-30 | $225.00K 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $297.00K 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $575.00K 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $1.14M 10-K · filed 2023-02-28 | |
| 2022-09-30 | $1.71M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $2.26M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $2.80M 10-Q · filed 2022-11-03 | $2.82M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $526.00K 10-K · filed 2022-02-15 | |
| 2020-12-31 | $2.55M 10-K · filed 2021-02-23 | |
| 2020-09-30 | $3.03M 10-Q · filed 2020-11-03 | |
| 2020-06-30 | $3.50M 10-Q · filed 2020-08-04 | |
| 2020-03-31 | $3.11M 10-Q · filed 2020-05-04 | |
| 2019-12-31 | $3.46M 10-K · filed 2020-02-24 | |
| 2019-09-30 | $770.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $1.15M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $1.52M 10-Q · filed 2019-05-09 | |
| 2019-01-31 | $2.80M 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |